Patel Anamika, Vought Valarie E, Swatkoski Stephen, Viggiano Susan, Howard Benny, Dharmarajan Venkatasubramanian, Monteith Kelsey E, Kupakuwana Gillian, Namitz Kevin E, Shinsky Stephen A, Cotter Robert J, Cosgrove Michael S
From the Department of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, New York 13210.
J Biol Chem. 2014 Jan 10;289(2):868-84. doi: 10.1074/jbc.M113.501064. Epub 2013 Nov 14.
The mixed lineage leukemia-1 (MLL1) core complex predominantly catalyzes mono- and dimethylation of histone H3 at lysine 4 (H3K4) and is frequently altered in aggressive acute leukemias. The molecular mechanisms that account for conversion of mono- to dimethyl H3K4 (H3K4me1,2) are not well understood. In this investigation, we report that the suppressor of variegation, enhancer of zeste, trithorax (SET) domains from human MLL1 and Drosophila Trithorax undergo robust intramolecular automethylation reactions at an evolutionarily conserved cysteine residue in the active site, which is inhibited by unmodified histone H3. The location of the automethylation in the SET-I subdomain indicates that the MLL1 SET domain possesses significantly more conformational plasticity in solution than suggested by its crystal structure. We also report that MLL1 methylates Ash2L in the absence of histone H3, but only when assembled within a complex with WDR5 and RbBP5, suggesting a restraint for the architectural arrangement of subunits within the complex. Using MLL1 and Ash2L automethylation reactions as probes for histone binding, we observed that both automethylation reactions are significantly inhibited by stoichiometric amounts of unmethylated histone H3, but not by histones previously mono-, di-, or trimethylated at H3K4. These results suggest that the H3K4me1 intermediate does not significantly bind to the MLL1 SET domain during the dimethylation reaction. Consistent with this hypothesis, we demonstrate that the MLL1 core complex assembled with a catalytically inactive SET domain variant preferentially catalyzes H3K4 dimethylation using the H3K4me1 substrate. Taken together, these results are consistent with a "two-active site" model for multiple H3K4 methylation by the MLL1 core complex.
混合谱系白血病-1(MLL1)核心复合物主要催化组蛋白H3赖氨酸4位点(H3K4)的单甲基化和二甲基化,并且在侵袭性急性白血病中经常发生改变。单甲基H3K4转化为二甲基H3K4(H3K4me1,2)的分子机制尚不清楚。在本研究中,我们报道人MLL1和果蝇三胸复合物(Trithorax)的异染色质抑制因子、增强子、三胸复合物(SET)结构域在活性位点一个进化保守的半胱氨酸残基处发生强烈的分子内自动甲基化反应,该反应被未修饰的组蛋白H3抑制。SET-I亚结构域中自动甲基化的位置表明,MLL1 SET结构域在溶液中的构象可塑性比其晶体结构所显示的要大得多。我们还报道,在没有组蛋白H3的情况下,MLL1会使Ash2L甲基化,但只有当它与WDR5和RbBP5组装成复合物时才会发生,这表明复合物内亚基的结构排列存在限制。利用MLL1和Ash2L自动甲基化反应作为组蛋白结合的探针,我们观察到,化学计量的未甲基化组蛋白H3能显著抑制这两种自动甲基化反应,但H3K4位点先前已发生单甲基化、二甲基化或三甲基化的组蛋白则不能。这些结果表明,在二甲基化反应过程中,H3K4me1中间体与MLL1 SET结构域的结合并不显著。与此假设一致,我们证明,与催化失活的SET结构域变体组装的MLL1核心复合物优先使用H3K4me1底物催化H3K4二甲基化。综上所述,这些结果与MLL1核心复合物对多个H3K4进行甲基化的“双活性位点”模型一致。